ECP 2019 Final Programme

Monday, 9 Sept 182 ECP 2019 · Nice Breakfast and Luncheon Industry Symposia 004 13:55–14:20 Making sense of NGS complexity: clinical decision support tools Markus Falk, Germany 005 14:20–14:30 Summary & future perspectives Marc Denis, France LS-08 Industry Symposium 13:00–14:30 Uranie/Calliope NSCLC and beyond: Practical Considera- tions for PD-L1 implementation (MSD) Chair: Jaafar Bennouna, France 001 13:00–13:05 Welcome and introduction Jaafar Bennouna, France 002 13:05–13:25 Relevance of PD-L1 testing in an evolving immuno-oncology landscape: overview and updates Jaafar Bennouna, France 003 13:25–13:45 PD-L1 immune-based scoring approaches in non-lung cancer Hans-Ulrich Schildhaus, Germany 004 13:45–14:10 Quality PD-L1 testing: an EQA perspective Mogens Vyberg, Denmark 005 14:10–14:30 Q&A/Closing remarks Jaafar Bennouna, France LS-09 Industry Symposium 13:00–14:30 Hermès From respectable to exceptional: advancing beyond existing PD-L1 test capabilities for histologic and cytologic NSCLC specimens (AstraZeneca) Chair: Paul Hofman, France 001 13:00–13:05 Welcome and introduction Paul Hofman, France 002 13:05–13:30 Solving PD-L1 test dilemmas once and for all Marius Ilié, France 003 13:30–13:55 Utility of cytologic specimens and preanalytical procedures for PD-L1 testing in NSCLC cytopathology Birgit Guldhammer Skov, Denmark 004 13:55–14:15 Strategies for addressing the intrinsic source of error associated with PD-L1 scoring and interpretation Bharat Jasani, Germany 005 14:15–14:25 Q&A Paul Hofman, France 006 14:25–14:30 Closing remarks Paul Hofman, France LS-06 Industry Symposium 13:00–14:30 Clio True precision oncology with next generation sequencing. Can one test fit all needs? (Thermo Fisher Scientific) Chair: Albrecht Stenzinger, Germany 001 13:05–13:25 In true precision oncology, one size cannot fill all needs Andy Felton, USA 002 13:25–13:45 Next generation sequencing in every pathology laboratory, are we ready? José Costa, Portugal 003 13:45–14:05 Reliable identification of gene fusions by targeted RNA sequencing Volker Endris, Germany 004 14:05–14:25 Biomarkers for immuno-oncology: tumour mutational load and beyond. The impact of a multidimensional approach Phil Jermann, Switzerland 005 14:25–14:30 Closing Albrecht Stenzinger, Germany